X0202 SCHEDULE 13G/A 0001493152-26-015540 0002077247 XXXXXXXX LIVE 1 Class A Common Stock, $0.0001 par value per share 06/30/2026 0001637715 OnKure Therapeutics, Inc. 68227Q105 6707 Winchester Circle, #400, Boulder, CO 80301 Rule 13d-1(c) Trails Edge Capital Partners, LP DE 1438456.00 0.00 1438456.00 0.00 1438456.00 N 3.6 IA PN See Item 4 for additional information. Trails Edge Biotechnology Master Fund, LP E9 1438456.00 0.00 1438456.00 0.00 1438456.00 N 3.6 PN See Item 4 for additional information. Ortav Yehudai X1 1438456.00 0.00 1438456.00 0.00 1438456.00 N 3.6 IN See Item 4 for additional information. OnKure Therapeutics, Inc. 6707 Winchester Circle, #400, Boulder, CO, 80301 This report on Schedule 13G/A (as amended, this "Schedule 13G") is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers". The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326. See Item 4 of the cover page of each Filer. Y As of June 30, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 1,438,456 shares (the "Shares") of Class A Common Stock, $0.0001 par value per share (the "Common Stock"), of OnKure Therapeutics, Inc. (the "Issuer"). The 1,438,456 Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 1,438,456 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 3.6% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 3.6% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 40,395,480 shares of Common Stock issued and outstanding as of May 4, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 5, 2026. 3.6 % 1,438,456.00 0.00 1,438,456.00 0.00 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1- Joint Filing Agreement, dated as of April 7, 2026, by and between Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on April 7, 2026). Trails Edge Capital Partners, LP /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai 08/14/2026 Trails Edge Biotechnology Master Fund, LP /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai 08/14/2026 Ortav Yehudai /s/ Ortav Yehudai 08/14/2026